Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

June 18, 2025 04:43 AM EDT | By News File Corp
 Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success
Image source: News File Corp

Thailand's National Innovation-Mangosteen-Based Immunotherapy Fights HIV/AIDS

Bangkok, Thailand--(Newsfile Corp. - June 18, 2025) - The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as "ByeByeHIV", characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title "ByeByeHIV with Thai Innovation."

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002.jpg

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002full.jpg

According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases, 10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV.

"ByeByeHIV" refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable.

The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage.

Based on the February 2024 publication titled "ByeByeHIV with Thai Innovation", (ByeByeHIV with Thai Innovation: https://www.scivisionpub.com/abstract-display.php?id=3167) the formula successfully helped two groups:

  • Group A: 24 HIV-positive individuals never on ARVs

  • Group B: 26 individuals previously treated with ARVs

By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV.

The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years. This suggests complete HIV eradication for the 15 individuals.

The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse.

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of

ARV Drugs (Group A) https://www.scivisionpub.com/abstract-display.php?id=3769

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of

ARV Drugs (Group B) https://www.scivisionpub.com/abstract-display.php?id=3770

These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives.

Professor Dr. Pichaet summarized, "This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured."

"This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs."

Contact Info:
Name: APCO Bangkok Office
Email: [email protected]
Organization: Asian Phytoceuticals Public Company Limited
Address: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, Thailand
Phone: 0-2646-4800
Website: https://www.apco.co.th

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255952


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media Incorporated (“Kalkine Media, we or us”), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used in the Content are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.